Abstract:BACKGROUND:Fibrosis is the single most important predictor of significant morbidity and mortality in patients with chronic liver disease. Established non-invasive tests for monitoring fibrosis are lacking, and new biomarkers of liver fibrosis and function are needed.AIM:To depict the process of liver fibrosis and look for novel biomarkers for diagnosis and monitoring fibrosis progression.METHODS:CCl4 was used to establish the rat liver fibrosis model. Liver fibrosis process was measured by liver chemical tests, liver histopathology, and Masson's trichrome staining. The expression levels of two fibrotic markers including α-smooth muscle actin and transforming growth factor β1 were assessed using immunohistochemistry and real-time polymerase chain reaction. Dynamic changes in metabolic proﬁles and biomarker concentrations in rat serum during liver fibrosis progression were investigated using ultra-performance liquid chromatography coupled to quadrupole time-of-flight mass spectrometry. The discriminatory capability of potential biomarkers was evaluated by receiver operating characteristic (ROC) curve analysis.RESULTS:To investigate the dynamic changes of metabolites during the process of liver fibrosis, sera from control and fibrosis model rats based on pathological results were analyzed at five different time points. We investigated the association of liver fibrosis with 21 metabolites including hydroxyethyl glycine, L-threonine, indoleacrylic acid, β-muricholic acid (β-MCA), cervonoyl ethanolamide (CEA), phosphatidylcholines, and lysophosphatidylcholines. Two metabolites, CEA and β-MCA, differed significantly in the fibrosis model rats compared to controls (P < 0.05) and showed prognostic value for fibrosis. ROC curve analyses performed to calculate the area under the curve (AUC) revealed that CEA and β-MCA differed significantly in the fibrosis group compared to controls with AUC values exceeding 0.8, and can clearly differentiate early stage from late stage fibrosis or cirrhosis.CONCLUSION:This study identified two novel biomarkers of fibrosis, CEA and β-MCA, which were effective for diagnosing fibrosis in an animal model.

Liver fibrosis alters the molecular structures of hepatic glycogen

Molecular Structure of Human-Liver Glycogen

Ethanol-induced Hepatic Steatosis is Modulated by Glycogen Level in the Liver

Single-cell Analysis Reveals Lysyl Oxidase (lox)+ Fibroblast Subset Involved in Cardiac Fibrosis of Diabetic Mice.

Molecular structure of glycogen in diabetic liver

Dynamic Changes of Key Metabolites During Liver Fibrosis in Rats.

Liver glycogen fragility in the presence of hydrogen-bond breakers

Proteomic Signature of Acute Liver Failure: from Discovery and Verification in a Pig Model to Confirmation in Humans.

Liver fibrosis: Pathophysiology and clinical implications

The importance of glycogen molecular structure for blood glucose control

Glucose Fluctuation Increased Hepatocyte Apoptosis under Lipotoxicity and the Involvement of Mitochondrial Permeability Transition Opening.

Liver Fibrosis and Altered Matrix Synthesis

Spatial metabolomics reveals glycogen as an actionable target for pulmonary fibrosis

Liver-fibrosis-activated transcriptional networks govern hepatocyte reprogramming and intra-hepatic communication

Metabolic Hallmarks of Hepatic Stellate Cells in Liver Fibrosis

Postprandial Glycogen Content Is Increased in the Hepatocytes of Human and Rat Cirrhotic Liver

Mechanisms of liver fibrosis in metabolic syndrome

Transcriptomics reveals immune-metabolism disorder in acute-on-chronic liver failure in rats

Matrisome Gene-Based Subclassification of Patients with Liver Fibrosis Identifies Clinical and Molecular Heterogeneities.

Mechanisms of liver fibrosis and its role in liver cancer